1.Biomimetic nanostructured materials: potential regulators for osteogenesis?
Michelle NGIAM ; Luong T H NGUYEN ; Susan LIAO ; Casey K CHAN ; Seeram RAMAKRISHNA
Annals of the Academy of Medicine, Singapore 2011;40(5):213-222
Nanostructured materials are gaining new impetus owing to the advancements in material fabrication techniques and their unique properties (their nanosize, high surface area-to-volume ratio, and high porosity). Such nanostructured materials mimic the subtleties of extracellular matrix (ECM) proteins, creating artifi cial microenvironments which resemble the native niches in the body. On the other hand, the isolation of mesenchymal stem cells (MSCs) from various tissue sources has resulted in the interest to study the multiple differentiation lineages for various therapeutic treatments. In this review, our focus is tailored towards the potential of biomimetic nanostructured materials as osteoinductive scaffolds for bone regeneration to differentiate MSCs towards osteoblastic cell types without the presence of soluble factors. In addition to mimicking the nanostructure of native bone, the supplement of collagen and hydroxyapatite which mimic the main components of the ECM also brings signifi cant advantages to these materials.
Biomimetics
;
instrumentation
;
methods
;
Bone Transplantation
;
Collagen Type I
;
Extracellular Matrix
;
Humans
;
Mesenchymal Stromal Cells
;
Nanostructures
;
Osteogenesis
;
Tissue Engineering
;
instrumentation
;
methods
2.Rapid Virologic Response to Brincidofovir in Children with Disseminated Adenovirus Infection
Shuk Ying CHAN ; Susan E. PROCKOP ; Farid BOULAD ; Genovefa A. PAPANICOLAOU ; Yeon Joo LEE
Infection and Chemotherapy 2021;53(3):572-577
Disseminated adenovirus infections (d-ADV) after hematopoietic cell transplant (HCT) are often fatal with limited treatment options. Brincidofovir (BCV) a lipid ester of cidofovir is developed for this indication. We report four pediatric HCT recipients with d-ADV treated successfully with BCV.
3.Rapid Virologic Response to Brincidofovir in Children with Disseminated Adenovirus Infection
Shuk Ying CHAN ; Susan E. PROCKOP ; Farid BOULAD ; Genovefa A. PAPANICOLAOU ; Yeon Joo LEE
Infection and Chemotherapy 2021;53(3):572-577
Disseminated adenovirus infections (d-ADV) after hematopoietic cell transplant (HCT) are often fatal with limited treatment options. Brincidofovir (BCV) a lipid ester of cidofovir is developed for this indication. We report four pediatric HCT recipients with d-ADV treated successfully with BCV.
4.Estimation and projection of the HIV epidemic trend among the migrant population in China.
XiaoJun MENG ; Lu WANG ; Susan CHAN ; Kathleen Heather REILLY ; ZhiHang PENG ; Wei GUO ; GuoWei DING ; ZhengWei DING ; QianQian QIN
Biomedical and Environmental Sciences 2011;24(4):343-348
OBJECTIVEThe migrant population is a vulnerable group for HIV infection in China. Understanding potential epidemic trends among migrants is critical for developing HIV preventative measures in this population.
METHODSThe Estimation and Projection Package (EPP) model was used to process prefecture and county-level surveillance data to generate HIV prevalence and epidemic trends for migrant populations in China.
RESULTSThe prevalence of HIV among migrants in 2009 was estimated at 0.075% (95% CI: 0.042%, 0.108%) in China. The HIV epidemic among migrants is likely to increase over the next 5 years, with the prevalence expected to reach 0.110% (95% CI: 0.070%, 0.150%) by 2015.
CONCLUSIONAlthough the 2009 estimates for the HIV/AIDS epidemic in China indicate a slower rate of increase compared with the national HIV/AIDS epidemic, it is estimated to persistently increase among migrants over the next 5 years. Migrants will have a strong impact on the overall future of the HIV epidemic trend in China and evidence-based prevention and monitoring efforts should be expanded for this vulnerable population.
China ; epidemiology ; Condoms ; Epidemics ; statistics & numerical data ; Female ; HIV Infections ; epidemiology ; Humans ; Male ; Models, Theoretical ; Prevalence ; Risk Factors ; Safe Sex ; Sexual Behavior ; Transients and Migrants
5.Effect of Using an Audiovisual CPR Feedback Device on Chest Compression Rate and Depth.
Jeremy C P WEE ; Mooppil NANDAKUMAR ; Yiong Huak CHAN ; Rowena S L YEO ; Kaldip KAUR ; V ANANTHARAMAN ; Susan YAP ; Marcus E H ONG
Annals of the Academy of Medicine, Singapore 2014;43(1):33-38
INTRODUCTIONThe aim of the study is to investigate the effect of using Automated External Defibrillator (AED) audiovisual feedback on the quality of cardiopulmonary resuscitation (CPR) in a manikin training setting.
MATERIALS AND METHODSFive cycles of 30 chest compressions were performed on a manikin without CPR prompts. After an interval of at least 5 minutes, the participants performed another 5 cycles with the use of real time audiovisual feedback via the ZOLL E-Series defibrillator. Performance data were obtained and analysed.
RESULTSA total of 209 dialysis centre staff participated in the study. Using a feedback system resulted in a statistically significant improvement from 39.57% to 46.94% (P=0.009) of the participants being within the target compression depth of 4 cm to 5 cm and a reduction in those below target from 16.45% to 11.05% (P=0.004). The use of feedback also produced a significant improvement in achieving the target for rate of chest compression (90 to 110 compressions per minute) from 41.27% to 53.49%; (P<0.001). The mean depth of chest compressions was 4.85 cm (SD=0.79) without audiovisual feedback and 4.91 (SD=0.69) with feedback. For rate of chest compressions, it was 104.89 (SD=13.74) vs 101.65 (SD=10.21) respectively. The mean depth of chest compression was less in males than in females (4.61 cm vs 4.93 cm, P=0.011), and this trend was reversed with the use of feedback.
CONCLUSIONIn conclusion, the use of feedback devices helps to improve the quality of CPR during training. However more studies involving cardiac arrest patients requiring CPR need to be done to determine if these devices improve survival.
Adult ; Audiovisual Aids ; Cardiopulmonary Resuscitation ; instrumentation ; methods ; Defibrillators ; Feedback ; Female ; Humans ; Male ; Manikins ; Middle Aged ; Pressure ; Prospective Studies ; Thorax ; Young Adult
6.Diagnostic thresholds for absolute systolic toe pressure and toe-brachial index in diabetic foot screening.
Chuan Guan NG ; Cherry Ya Wen CHEONG ; Wan Chin CHAN ; Sean Wei Loong HO ; Melissa Susan Li Ann PHUA ; Khalid ANUAR
Annals of the Academy of Medicine, Singapore 2022;51(3):143-148
INTRODUCTION:
Identifying peripheral arterial disease (PAD) during diabetic foot screening (DFS) is crucial in reducing the risk of diabetic foot ulcerations and lower limb amputations. Screening assessments commonly used include absolute systolic toe pressure (ASTP) and toe-brachial index (TBI). There is a lack of research defining the threshold values of both assessment methods. We aimed to compare the accuracy of ASTP and TBI and establish optimal threshold values of ASTP and TBI with reference to the internationally accepted ankle-brachial pressure index (ABPI) screening test, for a multiethnic diabetic population in Singapore.
METHODS:
A retrospective, observational study of DFS results from January 2017 to December 2017 was conducted. Receiver operating characteristic analysis was conducted for ASTP and TBI using the internationally accepted ABPI cut-off value of ≤0.9 to indicate PAD.
RESULTS:
A total of 1,454 patients with mean (standard deviation) age of 63.1 (12.4) years old were included. There were 50.8% men and 49.2% women, comprising 69.7% Chinese, 13.5% Indian, 10.1% Malay and 6.7% other ethnicities. Areas under the curve for ASTP and TBI were 0.89 (95% confidence interval [Cl] 0.85-0.94) and 0.94 (95% Cl 0.90-0.98), respectively, and the difference was statistically significant (P<0.001). Derived optimal threshold values to indicate ABPI≤0.9 for ASTP and TBI were <95.5mmHg (specificity 0.86, sensitivity 0.84) and <0.7 (specificity 0.89, sensitivity 0.95), respectively.
CONCLUSION
ASTP or TBI may be used to detect ABPI-determined PAD in DFS. The optimal threshold values derived from a multiethnic Asian diabetic population were <95.5mmHg for ASTP and <0.7 for TBI.
Ankle Brachial Index/methods*
;
Diabetes Mellitus/epidemiology*
;
Diabetic Foot/diagnosis*
;
Female
;
Humans
;
Male
;
Middle Aged
;
Peripheral Arterial Disease/diagnosis*
;
Retrospective Studies
;
Toes
7.Meeting Report: Translational Advances in Cancer Prevention Agent Development Meeting
Mark Steven MILLER ; Peter J. ALLEN ; Powel H. BROWN ; Andrew T. CHAN ; Margie L. CLAPPER ; Roderick H. DASHWOOD ; Shadmehr DEMEHRI ; Mary L. DISIS ; Raymond N. DUBOIS ; Robert J. GLYNN ; Thomas W. KENSLER ; Seema A. KHAN ; Bryon D. JOHNSON ; Karen T. LIBY ; Steven M. LIPKIN ; Susan R. MALLERY ; Emmanuelle J. MEUILLET ; Richard B.S. RODEN ; Robert E. SCHOEN ; Zelton D. SHARP ; Haval SHIRWAN ; Jill M. SIEGFRIED ; Chinthalapally V. RAO ; Ming YOU ; Eduardo VILAR ; Eva SZABO ; Altaf MOHAMMED
Journal of Cancer Prevention 2021;26(1):71-82
The Division of Cancer Prevention of the National Cancer Institute (NCI) and the Office of Disease Prevention of the National Institutes of Health co-sponsored the Translational Advances in Cancer Prevention Agent Development Meeting on August 27 to 28, 2020. The goals of this meeting were to foster the exchange of ideas and stimulate new collaborative interactions among leading cancer prevention researchers from basic and clinical research; highlight new and emerging trends in immunoprevention and chemoprevention as well as new information from clinical trials; and provide information to the extramural research community on the significant resources available from the NCI to promote prevention agent development and rapid translation to clinical trials. The meeting included two plenary talks and five sessions covering the range from pre-clinical studies with chemo/immunopreventive agents to ongoing cancer prevention clinical trials. In addition, two NCI informational sessions describing contract resources for the preclinical agent development and cooperative grants for the Cancer Prevention Clinical Trials Network were also presented.
8.Meeting Report: Translational Advances in Cancer Prevention Agent Development Meeting
Mark Steven MILLER ; Peter J. ALLEN ; Powel H. BROWN ; Andrew T. CHAN ; Margie L. CLAPPER ; Roderick H. DASHWOOD ; Shadmehr DEMEHRI ; Mary L. DISIS ; Raymond N. DUBOIS ; Robert J. GLYNN ; Thomas W. KENSLER ; Seema A. KHAN ; Bryon D. JOHNSON ; Karen T. LIBY ; Steven M. LIPKIN ; Susan R. MALLERY ; Emmanuelle J. MEUILLET ; Richard B.S. RODEN ; Robert E. SCHOEN ; Zelton D. SHARP ; Haval SHIRWAN ; Jill M. SIEGFRIED ; Chinthalapally V. RAO ; Ming YOU ; Eduardo VILAR ; Eva SZABO ; Altaf MOHAMMED
Journal of Cancer Prevention 2021;26(1):71-82
The Division of Cancer Prevention of the National Cancer Institute (NCI) and the Office of Disease Prevention of the National Institutes of Health co-sponsored the Translational Advances in Cancer Prevention Agent Development Meeting on August 27 to 28, 2020. The goals of this meeting were to foster the exchange of ideas and stimulate new collaborative interactions among leading cancer prevention researchers from basic and clinical research; highlight new and emerging trends in immunoprevention and chemoprevention as well as new information from clinical trials; and provide information to the extramural research community on the significant resources available from the NCI to promote prevention agent development and rapid translation to clinical trials. The meeting included two plenary talks and five sessions covering the range from pre-clinical studies with chemo/immunopreventive agents to ongoing cancer prevention clinical trials. In addition, two NCI informational sessions describing contract resources for the preclinical agent development and cooperative grants for the Cancer Prevention Clinical Trials Network were also presented.